Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in February.

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...

SpringWorks sells two rare tumors drugs in the US and has two precision oncology drugs in early-stage development.

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

U.S. President Donald Trump called Amazon Executive Chairman Jeff Bezos on Tuesday morning to complain about a report the ...

Merck KGaA plans to acquire SpringWorks Therapeutics (NASDAQ:SWTX) for approximately $3.9 billion, aiming to enhance its ...

The biggest M&A activity of the year arrived in the form of Merck KGaA’s earlier-disclosed agreement to buy Springworks Therapeutics Inc. for $47 per share in cash, which represents an equity value of ...

After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.

Health-care companies rose amid deal activity. Germany's Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology ...

This collection of health news covers a range of topics including criticisms of EU drug price proposals, new agreements ...

Laurence Norman - profile from The Wall Street Journal. News, articles, biography and photos.

Merck KGaA plans to acquire SpringWorks Therapeutics, a Connecticut-based specialist in biopharmaceuticals for severe rare diseases and cancer ...